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This phase I study evaluated the maximal tolerated dose of CPX-351 when administered sequentially with
allogeneic hematopoietic stem cell transplantation (HSCT) in patients with refractory acute leukemia.
CPX-351 is a novel liposomal formulation that combines cytosine arabinoside (ara-c) and daunorubicin in
a ﬁxed molar ratio of 5:1. Patients in cohorts of 3 were treated with CPX-351 followed by ﬂudarabine and
busulfan (Bu/Flu) conditioning at 4-week (schedule A) or 3-week (schedule B) intervals. CPX-351 doses were
escalated in 20-U/m2 increments starting at 60 U/m2 for 3 doses. Of the 36 patients enrolled, 29 were able to
undergo HSCT, and the other 7 (the majority on schedule A) did not proceed to HSCT because of rapid disease
progression. The maximal tolerated dose of CPX-351 was not reached at the 120 U/m2  3 dose level. All 29
patients who proceeded to HSCT demonstrated adequate neutrophil and platelet engraftment. The median
follow-up on the study for all 36 patients was 205 days (range, 20 to 996 days). The 1-year cumulative
incidence of relapse for the 36 patients was 60.1% (95% conﬁdence interval [CI], 43.4% to 77.3%), and that of
nonrelapse mortality was 23.8% (95% CI, 10.9% to 47.4%). The 1-year overall survival and leukemia-free
survival were 37% (95% CI, 21% to 53%) and 27% (95% CI, 13% to 43%), respectively. Our data suggest that
a phase II trial should incorporate CPX-351 120 U/m2  3 dosing on schedule B. Patients with good perfor-
mance status and those who achieve effective cytoreduction from CPX-351 derived the greatest beneﬁt.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Survival rates in adults with relapsed or primary refrac-
tory acute myelogenous leukemia (AML) remain poor [1-4].
Chemotherapy and/or radiotherapy in conjunction with
hematopoietic stem cell transplantation (HSCT) represents
the sole curative treatment [5]. Outcomes are signiﬁcantly
better if patients are in remission, however, and thus, despite
an increasing availability of compatible donors, many
patients do not undergo HSCT because of the failure to ach-
ieve disease control.
One strategy has been to attempt HSCT with active
leukemia; however, several large retrospective series have
shown that the administration of traditional high-dose
alkylating agentebased conditioning regimens, with or
without total body irradiation, is incapable of curing the
majority of these patients, owing to high relapse rates and
nonrelapse mortality (NRM) [5]. An alternative approach has
involved the use of a sequential schedule of antileukemic
chemotherapy followed by conditioning and HSCT; several
investigators have reported survival rates approaching 40%
in selected adults with refractory AML [6-8].
The novel agent CPX-351 is currently under investigation
in a phase III trial in patients with newly diagnosed AML.edgments on page 1045.
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13.04.013Each unit of CPX-351 is composed of 1.0 mg of cytarabine and
0.44 mg of daunorubicin. Preclinical studies have shown that
this ratio is highly synergistic in leukemia cell lines as well as
in primary AML cells. In addition, studies in mice demon-
strated a unique preferential uptake in the bone marrow
comparedwith other organs. The drug has a longmedian one
half-life of 31.1 hours for cytarabine and 21.9 hours for
daunorubicin, with both drugs and their metabolites
detectable for longer than 7 days after the last dose [9-14].
An initial clinical and pharmacokinetic study in adults with
relapsed or refractory AML, established a maximal tolerated
dose (MTD) was established at 101 U/m2on days 1, 3, and 5
[15]. Complete remissions were observed in AML patients
resistant to standard high-dose cytosine arabinoside (ara-c)
combination regimens. Apart from severemyelosuppression,
resulting in delayed bone marrow recovery, nonhematologic
toxicities were relatively mild and not dose-limiting. Further
studies in patients age >60 years with untreated AML
demonstrated enhanced efﬁcacy compared with daunoru-
bicin and ara-c, particularly in patients with secondary AML
[16]. Importantly, these studies demonstrated the safety of
CPX-351 in heavily pretreated and elderly patients with AML.
Based on preclinical observations of selective marrow
uptake of CPX-351 in mice, the relative lack of extra-
medullary toxicity, and the potential increased efﬁcacy
compared with standard anthracycline/ara-c combinations,
this agent is well suited for integration into a transplantation
conditioning regimen. Accordingly, we conducted the phase I
trial reported here.Transplantation.
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Evaluation and Deﬁnitions
The primary objective of this study was to establish the MTD and the
recommended phase II dose of CPX-351 when followed by HSCT. Regimen-
related toxicities refer to toxicities as a result of CPX-351 or its combination
with the conditioning regimen. The MTD was deﬁned as the highest dose
level of CPX-351 with an observed incidence of dose-limiting toxicity (DLT)
in 1 of 6 patients treated at a particular dose level. A DLT was deﬁned as any
grade 3 or 4 (fatal) event based on the Bearman Toxicity Scale for regimen-
related toxicities in transplantation [17], or failure to engraft by day þ35
post-HSCT. Neutrophil engraftment was deﬁned as the ﬁrst of 3 consecutive
days with an absolute neutrophil count of 500/mm3, and platelet
engraftment was deﬁned as the ﬁrst of 7 consecutive days of unsupported
platelet count of 20,000/mm3. The deﬁnitions of responses in patients
with AML were according to those of the International Working Group [18].
NRM was deﬁned as mortality from any cause in the absence of any
evidence of leukemia. Disease risk for patients with AML and acute
lymphoblastic leukemia (ALL) was scored according to the Center for
International Blood andMarrow Transplantation Research (CIBMTR) scoring
system for refractory leukemia [5]. Concomitant conditions were scaled
using the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI)
[19]. Cytogenetic risk was scored according to the Eastern Cooperative
Oncology Group (ECOG)/Cancer and Leukemia Group B classiﬁcation system
[20]. FLT-3mutationwas considered a poor-risk abnormality [21]. A regimen
was deﬁned as any number of cycles of a chemotherapy regimen given as
initial induction, consolidation or salvage therapy.
Eligibility
Adult patients age 18 years with AML, ALL, blast-phase chronic
myelogenous leukemia, or advanced myelodysplastic syndrome (MDS) who
were refractory to chemotherapy were eligible. Only patients with an HLA-
matched sibling donor or HLA-matched unrelated donor were allowed on
the study. Matching by high-resolution typing for HLA-A. -B, -C and -DRB1
loci was required. Further inclusion criteria included an ECOG performance
status of 2, left ventricular ejection fraction (LVEF) 50%, creatinine
clearance60mL/min, lung diffusion capacity for carbonmonoxide45% of
predicted (corrected for hemoglobin), transaminase values 3 times
the upper limit of normal, and total serum bilirubin 1.5 times the upper
limit of normal. Patients with a cumulative previous anthracycline dose of
368 mg/m2 of daunorubicin or equivalent were excluded as well.
Treatment Plan
CPX-351
CPX-351 (Celator Pharmaceuticals, Princeton, NJ) was administered in
a dose-escalated fashion on days -28, -26, and -24 (schedule A) or on days
-21, -19, and -17 (schedule B). Patients were entered in cohorts of 3 starting
at a dose of 60 U/m2 infused over 90 minutes and escalated in 20-U/m2
increments until a DLT was observed (Figure 1).
Conditioning regimen
The conditioning regimen consisted of i.v. busulfan 3.2 mg/kg/day and
ﬂudarabine 30 mg/m2/day on days -6 to -3. Based on concerns about pro-
longed and high marrow concentrations of CPX-351 and the effect on
engraftment, patients were initially enrolled on schedule A. Once timely
engraftment of the ﬁrst 3 cohorts was observed, schedule B was initiated
(Figure 1). The rationale for studying schedule B was to reduce the duration
of neutropenia and diminish the possibility of leukemic regrowth during the
interval between the administration of CPX-351 and the start of the
conditioning regimen.
Graft-versus-host disease prophylaxis and supportive treatment
Graft-versus-host disease (GVHD) prophylaxis consisted of metho-
trexate and tacrolimus. Methotrexate was given at a dose of 5 mg/m2 i.v. on
days 1, 3, 6, and 11. The ﬁrst 3 patients received 10 mg/m2, but the dose was
reduced because of severe mucositis. Tacrolimus was started on day -3 at
0.03 mg/kg/24 hours as a continuous infusion, with the dose adjusted to
achieve a trough level of 10-15 ng/mL. In the absence of GVHD, tacrolimus
was continued for 3 months in patients receiving a matched related graft
and for 6 months in patients receiving a matched unrelated graft. Infection
prophylaxis was provided with ﬂuconazole 200 mg twice daily, valacyclovir
400 mg twice daily starting on day þ1, and sulfamethoxazole-trimethoprim
800 -160 mg, 2 tablets 3 times a week starting on day þ30.
Statistical Considerations
This was a phase I trial to determine the MTD of CPX-351 when followed
by HSCT in a sequential regimen. Patients were treated in cohorts of 3,
and the CPX-351 dose was escalated to the next dose level if no DLT was
experienced by any of the 3 patients. Patients were replaced in theirrespective cohorts if they were not evaluable for engraftment owing to
failure to proceed to transplantation or death before engraftment for
reasons other than regimen-related toxicities (ie, disease progression or
infections). Cumulative incidence of relapse, NRM, LFS, and OS were
secondary endpoints. LFS and OS were estimated by Kaplan-Meier survival
analysis, and the log-rank test was used to compare LFS/OS among cate-
gories of prognostic variables of interest. All P values are 2-sided, with
statistical signiﬁcance evaluated at the a ¼ 0.05 level. The 95% conﬁdence
intervals (CIs) for median LFS/OS and 1-year LFS/OS were calculated to
assess the precision of the obtained estimates. All analyses were performed
with SPSS version 20.0 (IBM, Armonk, NY) and Stata version 12.0 (StataCorp,
College Station, TX).
Study Conduct
This phase I study (ClinicalTrial.gov identiﬁer NCT00875693) was con-
ducted at Weill Cornell Medical College/New York Presbyterian Hospital in
according to the modiﬁed Declaration of Helsinki. The local Institutional
Review Boards approved the protocol. All patients were informed of the
investigational nature of the study and provided written informed consent.
RESULTS
Patient, Donor, and Transplantation Characteristics
Between June 2009 and October 2011, 36 patients were
entered into the study. One patient with refractory AML
received 1 dose of CPX-351 but did not receive further
treatments on the protocol when the planned unrelated
donor suddenly became unavailable. Six other patients
received CPX-351 but did not proceed to transplantation
because of rapid disease progression (n ¼ 5) and multi-
bacterial infections (n ¼ 1). One patient with high-grade
refractory MDS received CPX-351, but the transplantation
was delayed by 8 weeks because of sepsis. Twenty-eight
patients received the planned HLA-compatible grafts. Thus,
out of 36 patients, only 29 proceeded to transplantation.
The median age of the enrolled patients was 59 years
(range, 27 to 71 years); 16 patients (44%) were age60 years,
and 26 (72%) were age 50 years. The majority of patients
had refractory AML (30 of 36); 29 patients had circulating
blasts (13 with antecedent MDS or MPD, 3 patients had
secondary leukemia, and 2 patients had undergone previous
HSCT. Patients were heavily pretreated; 12 patients with
AML had received 3 previous regimens. For patients with
AML and ALL (32 patients total), the median CIBMTR risk
score was 3; 22 patients (69%) had a score 3. The median
HSCT-CI was 3, and 22 patients (61%) had a score 3. Six
patients had a documented invasive fungal infection (IFI),
and 8 patients had known bacterial infection requiring i.v.
antibiotics up to the day of initiation of CPX-351. Character-
istics of the 36 patients and 29 HSCTs performed are detailed
in Table 1.
MTD of CPX351 Given before Bu/Flu Conditioning
The dose of CPX-351 was escalated up to 120 U/m2 on
both schedule A and schedule B. No DLTs were observed on
either schedule. One patient received CPX-351 at 140 U/m2
and experienced a transient decrease in LVEF in the setting of
leukemia progression and multibacterial infections. Because
further dose escalation of CPX-351 inherently increased the
cumulative anthracycline dose (3 doses of 140 U/m2 contains
168mg/m2 of daunorubicin), we decided to stop further dose
escalation (without reaching a DLT as deﬁned previously)
and to consider the 120 U/m2 dose safe for further study
(Table 2).
Engraftment
Twenty-seven patients received the sequential treatment
according to the protocol timeline and were evaluable for
assessing engraftment. All evaluable patients had met the
Figure 1. Treatment schemes for schedules A and B.
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a median time of 17 and 21 days, respectively. Chimerism
studies performed in the 25 evaluable patients on or about
day þ30 found a median donor CD3 of 80% (range, 7% to
100%) and a median donor CD33 of 94% (range, 2% to 100%).
Disease Response
Baseline bone marrow data recorded within 4 weeks of
initiation of CPX-351 were available for 31 of the 36 enrolled
patients. Baseline marrow evaluation was omitted in 5
patients who had a high circulating blast burden. Day þ14
bone marrow evaluation was performed in 34 patients, but
was not done in 2 patients with persistent circulating blasts.
Fourteen patients (39%) had 5% marrow blasts, and 22
patients had >5% blasts (20 patients by marrow evaluation
and 2 patients by circulating blasts) on day 14. Twenty-nine
patients proceeded to transplantation. One patient died (on
day þ12), and thus 28 patients were evaluable for disease
response. Day þ30 bone marrow evaluation uncovered 2
patients with persistent leukemic blasts, 4 patients were in
morphological complete remission (CR) but had evidence of
persistent phenotypic and/or cytogenetic abnormalities, and
22 patients were in CR or CRi. No correlation was detected
between CPX-351 dose level and the degree of cytoreduction
on day 14 after starting CPX-351 or disease response at the
day þ30 bone marrow evaluation.
OS and LFS
The median follow-up duration on the study for all 36
patients was 205 days (range, 20 to 996 days). For surviving
patients (n¼ 11), the median follow-up was 377 days (range,
111 to 996 days). The 1-year cumulative incidence of relapse
was 60.1% (95% CI, 43.4% to 77.3%). The 1-year cumulative
incidence of NRMwas 23.8% (95% CI, 10.9% to 47.4%), with the
cause of death being acute GVHD in 3 patients, sepsis in 2
patient, recurrent brain tumor in 1 patient, and liver failure
in 1 patient at 15 months posttransplantation attributed to
iron overload. A total of 25 patients died (69%), 7 patients
remained alive without leukemia (19%), and 4 more patientsremained alive after leukemia relapse (11%), resulting in
a median OS of 251 days (95% CI, 173 to 329 days) and
a 1-year OS of 37% (95% CI, 21% to 53%). The median LFS was
98 days (95% CI,16 to 181 days), with a 1-year LFS of 27% (95%
CI, 13% to 43%) (Figure 2A and B). On univariate analysis, the
following factors were signiﬁcant (or borderline signiﬁcant)
for improved LFS and OS in all patients: day 14 blasts 5%
(P ¼ .02 for LFS and P ¼ .09 for OS) and ECOG score 1 (P <
.0001 for LFS and P ¼ .001 for OS) (Figure 2C and D). HSCT-CI
2 was not signiﬁcantly related to improved LFS and OS (P ¼
.83 for LFS and P ¼ .38 for OS). For the patients with AML,
cytogenetic risk other than poor risk and FLT 3 mutation was
associated with improved LFS and OS (P ¼ .01 for LFS and P ¼
.004 for OS) and CIBMTR risk score 2 was associated with
improved LFS and OS (P ¼ .09 for LFS and P ¼ .02 for OS).
Disease status (primary induction failure versus refractory
relapse), time from diagnosis to HSCT, and number of
chemotherapy regimens had no effect on outcomes.Schedules A and B
Twenty-one patients were enrolled on schedule A and 15
patients were enrolled on schedule B. Fifteen patients pro-
ceeded to HSCT on schedule A, and 14 did so on schedule B.
Seven patients (6 on schedule A and 1 on schedule B) did not
proceed to HSCT. There were no signiﬁcant differences in
engraftment kinetics or outcomes between patients who
underwent HSCT on schedule A and those who did so on
schedule B.GVHD
The 1-year cumulative incidence of grade II-IV acute
GVHD (aGVHD)was 36.1% (95% CI, 20.2% to 59.0%). Grade II-IV
and grade III-IV aGVHD affected 9 and 6 patients respectively.
Six patients had lower gastrointestinal aGVHD, and 3 patients
had upper gastrointestinal aGVHD. Two patients had grade I
skin aGVHD, and no patients had liver aGVHD. Chronic GVHD
affected 3 patients, all 3 with skin involvement and 2 with
lung involvement.
Table 1
Patient Characteristics
Characteristic Value
Number 36
Proceeded to transplantation, n 29
Age, yrs, median (range) 59 (26-72)
Sex, n
Male 14
Female 22
Donor, n (%)
MRD 12 (41)
MUD 17 (59)
Disease
AML, n (%) 30 (83)
PIF, n* 10
RR, ny 20
ALL, n 2
MDS, n 3
CML blast phase, n 1
Previous regimens (AML), n
1 4
2 14
3 12
ECOG score
Median/range 1 (0-3)
1, n 23
2, n 13
HSCT-CI score
Median/range 3 (0-11)
2, n 14
3, n 22
CIBMTR risk score (AML and ALL)
Median (range) 3 (1-6)
2, n 10
3, n 22
Cytogenetics (AML), n
Intermediate 11
Poor 13
FLT-3 mutated 6
Time from diagnosis to study entry, days
Median 270
Range 64-1162
Regimens before study entry (AML), n
Median 2
Range 1-5
Antecedent MDS or MPD, n 13
Treatment-related leukemia, n 4
Previous allogeneic SCT, n 2
Day 14 bone marrow blasts, nz
5% 14
>5% 22
* Primary induction failure.
y Refractory relapse.
z Day 14 after starting CPX-351.
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Organ toxicities (Table 3) and infectious events were
recorded from the day of starting CPX-351 until the day of
discharge, relapse, or NRM, whichever came ﬁrst. Cardiac
toxicity was followed indeﬁnitely in all long-term survivors.
Stomatitis was the most common toxicity, observed in all 29
patients who underwent HSCT. Three patients experiencedTable 2
The Distribution of Patients on Schedules A and B
CPX Dose Level, U/m2 Schedule A
(n ¼ 21)
Schedule B
(n ¼ 15)
Total
(n ¼ 36)
60 9 4 13
80 4 3 7
100 3 5 8
120 4 3 7
140 1 0 1a transient decrease in LVEF in the setting of severe sepsis. In
all 3 cases, cardiac function returned to baseline after the
infection was treated. Liver toxicity, as manifested by trans-
aminitis and/or hyperbillirubinemia, was uncommon, and no
patient developed signs of veno-occlusive disease. One
patient died in remission more than 15 months after trans-
plantation from liver failure due to hepatic hemosiderosis.
Coincidentally, this patient was heterozygous for H63D
hemochromatosis mutation, which is common in the general
population.The etiology of this patient’s liver failure is not
clear, given that H63D mutation is not associated with clin-
ical hemochromatosis [22].
Neutropenia-related fever was universally seen in all
patients enrolled on the trial. A documented bacterial
infection, primarily bacteremia, occurred in 25 patients.
Infectious events were counted during the period between
the initiation of CPX-351 and discharge from the hospital,
relapse, or NRM. There were 52 events of bacterial and 6
events of invasive fungal infections (3 presumptive, I prob-
able, and 2 proven). One patient had a positive respiratory
culture for parainﬂuenza A before conditioning. Viral reac-
tivation events were not counted as infections.
DISCUSSION
CPX-351 is a novel liposomal daunorubicin/ara-c
compound currently undergoing clinical development as
a single agent for treating adults with AML. In this initial
dose- and schedule-ﬁnding study, doses of CPX-351 at and
above the MTD as a single agent were given safely sequen-
tially with Bu/Flu conditioning in patients with active
leukemia. Apart from signiﬁcant oral mucositis, the regimen-
related toxicities observed did not appear to be greater than
those expected with Bu/Flu conditioning alone. Importantly,
no cardiac toxicities were attributed to CPX-351. Patients
with previous high anthracycline exposure were excluded
from this trial, however. Because further dose escalation
would preclude the use of this regimen in many patients
with AML, who are routinely treated with high-dose
anthracycline therapy, the recommended phase 2 dosage
regimen of CPX-351 in conjunction with Bu/Flu conditioning
is 3 doses of 120 U/m2.
Based on observations from this study, as well as ﬁndings
from the phase 1 nontransplantation trial, patients should
not receive a CPX-351ebased regimen in which the
prescribed dose of CPX351 will result in a cumulative
anthracycline exposure above accepted safety levels.
Initially, out of concern for the possibility of delayed
engraftment, the interval between completion of the last
dose of CPX-351 and the start of pretransplantation condi-
tioning was planned as 24 days. Timely engraftment
occurred in all 12 patients, but the long delay led to leukemic
regrowth in a signiﬁcant number of patients, precluding
them from proceeding to HSCT. In a subsequent cohort of
patients treated at a 17-day interval, engraftment and
toxicities were not affected, and only 1 of 15 of patients failed
to proceed to HSCT. These observations suggest that reducing
the interval between cytoreduction with CPX-351 and the
start of pretransplantation conditioning is advantageous in
decreasing the complications that preclude HSCT. Whether
a further reduction in the interval between cytoreduction
with CPX-351 and the start of the conditioning regimen
would lead to better outcomes awaits evaluation in a future
study.
With regard to efﬁcacy, given our limited data, it is
impossible to know whether the CPX-351ebased regimen is
Figure 2. Kaplan-Meier analyses for all patients (n ¼ 36). (A) LFS. (B) OS. (C) LFS by day 14 blasts. (D) OS by day 14 blasts.
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Table 3
Organ Toxicities by Bearman’s Toxicity Scale
Toxicity
Grade 1 Grade 2 Grade 3
Cardiac toxicity 0 3 0
Bladder toxicity 0 0 0
Renal toxicity 0 1 0
Pulmonary toxicity 0 2 0
Hepatic toxicity 0 2 0
Central nervous system toxicity 0 0 0
Stomatitis toxicity 10 19 0
Gastrointestinal toxicity 0 2 0
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tioning regimens that have incorporated more speciﬁc anti-
leukemic agents, such as amsacrine and clofarabine [6,8].
The high rates of relapse and NRM still pose major chal-
lenges to the success of HSCT for refractory leukemia. Our
study is no exception. Nonetheless, 2 observations from this
study may be helpful in planning future trials of HSCT for
patients with active leukemia. Patients with >5% blasts after
CPX-351 administration and before the start of conditioning
therapy had signiﬁcantly worse LFS and OS compared with
patients with<5% blasts. One could argue that these patients
should not undergo HSCT. Similar observations of the
predictive value of pretransplantation blast percentage have
been reported by other groups [8]. In addition, it may be
possible that the signiﬁcant reduction in AML burden
achievable with this approach will allow for the possible
eradication of minimal residual disease through the addition
of posttransplantation antileukemic therapies, including the
preemptive infusion of donor lymphocytes [6] and the
administration of hypomethylating agents [23] or FLT-3
inhibitors [24], among other strategies. The second obser-
vation from this trial is that patients with a low performance
status and more extensive chemotherapy exposure before
entry fared poorly. This suggests that earlier recognition of
leukemia resistance, based on well-established predictive
models [1-4], not only will allow for HSCT in less heavily
pretreated patients with better performance status, but also
will potentially diminish the resistance of the surviving
leukemic clone [25].ACKNOWLEDGMENTS
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